Puma Biotechnology, Inc. PBYI
Set alert
10.44 USD -0.10 -0.95%
At close · Oct 30
10.72 +0.28 +2.67%
After hours · Oct 30, 7:59 PM ET
10.36 Day range 10.65
4.58 52-week range 11.50
- YTD
- +75.46%
- 1 year
- +91.21%
- Open
- 10.56
- Prev close
- 10.54
- Mkt cap
- 538.91M
- Vol
- 339.54K
- Avg vol
- 333.19K
- EPS
- 0.51
- P/E
- 20.47
- Div yield
- 0.00%
More statistics
- Low
- 10.36
- High
- 10.65
- Forward P/E
- 11.71
- Beta
- 1.08
- Short ratio
- 5.09
- Inst. own
- 67.74%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.94
- 200-d avg
- 3.58
- 1y target
- 4.33
2Y chart
Events in this range
- Nov 7, 2024Earnings: 0.45; estimate 0.35; surprise 28.57%
- Nov 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 20, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 23, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (86)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| RSI: Overbought | Apr 8, 2026 | 6 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| RSI: Overbought | Feb 25, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 10, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 27, 2026 | 9 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 9, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 2, 2026 | 10 months ago |
| RSI: Overbought | Dec 26, 2025 | 10 months ago |
| SMA: Bullish | Dec 3, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| SMA: Bullish | Nov 18, 2025 | 11 months ago |
| SMA: Bearish | Nov 12, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 7, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 7, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 21, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| RSI: Overbought | Aug 21, 2025 | 1 year ago |
| RSI: Overbought | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Aug 8, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 18, 2025 | 1 year ago |
| SMA: Bearish | Jul 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 20, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| SMA: Bearish | May 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 17, 2025 | 1 year ago |
| RSI: Overbought | Feb 28, 2025 | 1 year ago |
| SMA: Bullish | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
Key statistics
- Market cap
- 137.94M
- Enterprise value
- 124.64M
- Trailing P/E
- 5.98
- Forward P/E
- 11.71
- PEG ratio
- 0.00
- Price / sales
- 0.57
- Price / book
- 1.94
- EPS (TTM)
- 0.47
- Beta
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 9.54%
- Revenue (TTM)
- 243.57M
- Revenue growth
- 43.50%
- Free cash flow
- 32.70M
- Total cash
- 96.72M
- Total debt
- 86.37M
- Return on equity
- 42.32%
- Shares outstanding
- 49.09M
- Short % of float
- 6.74%
- 50-day average
- 2.94
- 200-day average
- 3.58
Analyst view
Consensus: none
Price target (mean) 4.33 -58.5% downside
Now 10.44
- Target (low)
- 2.00
- Target (mean)
- 4.33
- Target (high)
- 7.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate 0.14.
Financials — quick view
PBYI Revenue — quarterly 56.50M
PBYI Net income — quarterly 8.19M
PBYI EPS — quarterly 0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.35 | 0.45 | +0.10 | +28.57% |
| Aug 1, 2024 | Jun 1, 2024 | -0.10 | -0.05 | +0.05 | +50.00% |
| May 2, 2024 | Mar 1, 2024 | -0.16 | -0.05 | +0.11 | +68.75% |
| Feb 29, 2024 | Dec 1, 2023 | 0.37 | 0.31 | -0.06 | -16.22% |
| Nov 2, 2023 | Sep 1, 2023 | 0.15 | 0.17 | +0.02 | +13.33% |
| Aug 3, 2023 | Jun 1, 2023 | 0.07 | 0.10 | +0.03 | +42.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pumabiotechnology.com
News
- Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
- Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
- 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
- Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript
- Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)
- PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
- Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung Cancer
- Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
- Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Your note
Sign in to keep a note on PBYI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUERBACH ALAN H | Chief Executive Officer | Sale | Jul 16, 2024 | 7,063,520 |
| DORVAL ALLISON | Director | Stock Award(Grant) | Jun 17, 2024 | 60,000 |
| HUNT DOUGLAS M | Officer | Sale | Jul 16, 2024 | 133,227 |
| LUDWIG JEFFREY JEROME | Officer | Sale | Jul 16, 2024 | 118,388 |
| MILLER MICHAEL PATRICK | Director | Sale | Aug 11, 2024 | 47,000 |
| MOYES JAY M | Director | Stock Award(Grant) | Jun 17, 2024 | 48,322 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.80% | 3,827,223 | 10.75M | Sep 29, 2024 |
| Vanguard Group Inc | 7.41% | 3,636,191 | 10.22M | Sep 29, 2024 |
| Frazier Life Sciences Management, L.P. | 6.24% | 3,062,558 | 8.61M | Sep 29, 2024 |
| Millennium Management Llc | 5.87% | 2,880,888 | 8.10M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 4.01% | 1,968,999 | 5.53M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 3.61% | 1,772,413 | 4.98M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.59% | 1,271,564 | 3.57M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.20% | 1,080,781 | 3.04M | Oct 30, 2024 |
| Vanguard Explorer Fund, Inc. | 1.58% | 777,390 | 2.18M | Jul 30, 2024 |
| Avantis U.S. Small Cap Value ETF | 1.46% | 718,454 | 2.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 585,850 | 1.65M | Sep 29, 2024 |
| Vanguard Strategic Equity Fund | 1.10% | 540,434 | 1.52M | Sep 29, 2024 |